Model the cost-to-value path of your drug asset.
AssetLens estimates development costs, commercial potential, and NPV across go-alone and outlicensing scenarios.
How much revenue could this asset generate?
- Market size & patient population
- Pricing assumptions & therapy positioning
- Market share & adoption scenarios
- Year-by-year revenue forecast
What kind of licensing deal could this asset support?
- Comparable licensing deals
- Upfront, milestones & royalties
- Stage-based deal logic
- Negotiation evidence for BD teams
How much will it cost to move this asset forward?
- Clinical development cost by phase
- Manufacturing & launch investment
- Commercialization cost assumptions
- Cost timeline & capital planning
Which path creates the strongest business case: develop, license, or wait?
- Go-alone scenario
- Outlicense-at-IND scenario
- Outlicense after Phase 1 / Phase 2 scenario
- Risk-adjusted business case
Real implementations – adapted to each client’s data, infrastructure, and operational needs.
Trusted by Industry Leaders:
Get in touch with us.
We’re here to assist you.
